TREACE MEDICAL CONCEPTS Files 8-K on Operations & Financials
Ticker: TMCI · Form: 8-K · Filed: 2024-01-08T00:00:00.000Z
Sentiment: neutral
Topics: financial-condition, results-of-operations, 8-K, corporate-update
TL;DR
**TMCI just dropped an 8-K on its financials, get ready for potential stock movement.**
AI Summary
TREACE MEDICAL CONCEPTS, Inc. filed an 8-K on January 8, 2024, to report on its results of operations and financial condition. This filing indicates that the company is providing an update on its financial performance, which is crucial for investors to understand the company's current health and future prospects. For shareholders, this matters because it offers transparency into how the company is performing, potentially influencing stock price based on whether the results meet or exceed expectations.
Why It Matters
This filing provides an update on the company's financial health, which is essential for investors to assess its performance and make informed decisions about buying, holding, or selling the stock.
Risk Assessment
Risk Level: low — This 8-K is a routine disclosure of financial information, which generally carries a low risk unless the disclosed information is unexpectedly negative.
Analyst Insight
Investors should look for the specific financial details that will be disclosed under 'Results of Operations and Financial Condition' to understand the company's performance and potential future trajectory. This filing itself is a procedural update, but the content it refers to will be critical.
Key Numbers
- 001-40355 — Commission File Number (Identifies the company's registration with the SEC.)
- 47-1052611 — IRS Employer Identification Number (Unique tax identification for the company.)
- (904) 373-5940 — Business Phone Number (Direct contact for the company's business operations.)
Key Players & Entities
- TREACE MEDICAL CONCEPTS, Inc. (company) — the registrant filing the 8-K
- January 8, 2024 (date) — date of earliest event reported and filing date
- Delaware (company) — state of incorporation for TREACE MEDICAL CONCEPTS, Inc.
- 001-40355 (dollar_amount) — Commission File Number
- 47-1052611 (dollar_amount) — IRS Employer Identification Number
- 100 Palmetto Park Place (company) — address of principal executive offices
- Ponte Vedra, Florida 32081 (company) — city, state, and zip code of principal executive offices
- (904) 373-5940 (dollar_amount) — registrant's telephone number
- TMCI (company) — trading symbol for Common Stock
- The Nasdaq Global Select Market (company) — exchange on which Common Stock is registered
FAQ
What is the purpose of this 8-K filing by TREACE MEDICAL CONCEPTS, Inc.?
The purpose of this 8-K filing, dated January 8, 2024, is to report on the 'Results of Operations and Financial Condition' and 'Financial Statements and Exhibits' of TREACE MEDICAL CONCEPTS, Inc., as indicated by the 'ITEM INFORMATION' sections.
What is the trading symbol and the exchange where TREACE MEDICAL CONCEPTS, Inc.'s Common Stock is registered?
TREACE MEDICAL CONCEPTS, Inc.'s Common Stock, with a $0.001 par value per share, trades under the symbol 'TMCI' and is registered on 'The Nasdaq Global Select Market'.
What is the earliest event reported date for this 8-K filing?
The 'Date of Report (Date of earliest event reported)' for this 8-K filing is 'January 8, 2024'.
Where are the principal executive offices of TREACE MEDICAL CONCEPTS, Inc. located?
The principal executive offices of TREACE MEDICAL CONCEPTS, Inc. are located at '100 Palmetto Park Place, Ponte Vedra, Florida 32081'.
Is TREACE MEDICAL CONCEPTS, Inc. classified as an emerging growth company?
No, the filing indicates with a '☐' (unchecked box) that TREACE MEDICAL CONCEPTS, Inc. is not an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Filing Stats: 506 words · 2 min read · ~2 pages · Grade level 10.7 · Accepted 2024-01-08 08:16:17
Key Financial Figures
- $0.001 — nge on which registered Common Stock, $0.001 par value per share TMCI The Nasdaq
Filing Documents
- tmci-20240108.htm (8-K) — 51KB
- tmci-ex99_1.htm (EX-99.1) — 31KB
- img32504678_0.jpg (GRAPHIC) — 5KB
- 0000950170-24-002719.txt ( ) — 208KB
- tmci-20240108.xsd (EX-101.SCH) — 28KB
- tmci-20240108_htm.xml (XML) — 4KB
02. Results of Operations and Financial Condition
Item 2.02. Results of Operations and Financial Condition. On January 8, 2024, Treace Medical Concepts, Inc. issued a press release regarding certain preliminary unaudited financial results for the quarter and year-end December 31, 2023. A copy of the press release is furnished as Exhibit 99.1 to this Form 8-K. This information furnished under Item 2.02 of Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities of that section, and shall not be deemed incorporated by reference into any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.
01
Item 9.01
Financial Statements and Exhibits
Financial Statements and Exhibits. Exhibit No. Description 99.1 Press Release of Treace Medical Concepts, Inc. issued on January 8, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. TREACE MEDICAL CONCEPTS, INC. Date: January 8, 2024 By: /s/ Mark L. Hair Mark L. Hair Chief Financial Officer